Lung Cancer
FDA Approves Foundation Medicine's Liquid Biopsy Test as CDx for Novartis' Tabrecta in NSCLC
The blood-based test is the second Foundation Medicine assay approved to ID patients eligible for the drug due to mutations leading to MET exon 14 skipping.
Genetron Health Receives CE Mark for Lung Cancer Sequencing Assay
The company has been commercializing the assay in China but believes that its technology will also be attractive to labs outside the country looking to bring NGS testing in house.
Quest Diagnostics to Offer Biocept's Target Selector NGS Lung Cancer Test
The liquid biopsy test is intended for identifying genetic mutations to guide therapy in patients with advanced non-small cell lung cancer.
The eNRGy trial demonstrated zenocutuzumab was the first prospective clinical validation of NRG1 fusions as actionable oncogenic drivers.
Biodesix, Datavant Join in Lung Cancer Data Partnership
Datavant will anonymize lung cancer records from the Biodesix biobank and add real-world data to aid researchers and biopharma companies.